RAD50 is altered in 1.63% of malignant solid tumor patients [3].

RAD50 is an inclusion criterion in 27 clinical trials for malignant solid tumor, of which 22 are open and 5 are closed. Of the trials that contain RAD50 status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 7 are phase 1/phase 2 (4 open), and 9 are phase 2 (9 open) [4].

RAD50 is altered in 0.95% of breast carcinoma patients [3].

RAD50 is an inclusion criterion in 20 clinical trials for breast carcinoma, of which 16 are open and 4 are closed. Of the trials that contain RAD50 status and breast carcinoma as inclusion criteria, 6 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [4].

RAD50 is altered in 0.73% of prostate adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 18 clinical trials for prostate adenocarcinoma, of which 17 are open and 1 is closed. Of the trials that contain RAD50 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (14 open), and 2 are phase 3 (2 open) [4].

RAD50 is altered in 1.05% of ovarian carcinoma patients [3].

RAD50 is an inclusion criterion in 14 clinical trials for ovarian carcinoma, of which 10 are open and 4 are closed. Of the trials that contain RAD50 status and ovarian carcinoma as inclusion criteria, 5 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [4].

RAD50 is altered in 0.73% of prostate carcinoma patients [3].

RAD50 is an inclusion criterion in 13 clinical trials for prostate carcinoma, of which 10 are open and 3 are closed. Of the trials that contain RAD50 status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (1 open) [4].

RAD50 is an inclusion criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain RAD50 status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

RAD50 is an inclusion criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain RAD50 status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

RAD50 is altered in 1.01% of pancreatic adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 6 clinical trials for pancreatic adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain RAD50 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].

RAD50 is altered in 1.59% of gastric carcinoma patients [3].

RAD50 is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD50 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.56% of small cell lung carcinoma patients [3].

RAD50 is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain RAD50 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [4].

RAD50 is altered in 1.14% of adenocarcinoma of the gastroesophageal junction patients [3].

RAD50 is an inclusion criterion in 5 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 4 are open and 1 is closed. Of the trials that contain RAD50 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [4].

RAD50 is altered in 3.74% of endometrial carcinoma patients [3].

RAD50 is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain RAD50 status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.51% of non-small cell lung carcinoma patients [3].

RAD50 is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain RAD50 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

RAD50 is altered in 3.04% of melanoma patients [3].

RAD50 is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain RAD50 status and melanoma as inclusion criteria, 3 are phase 2 (3 open) [4].

RAD50 is altered in 2.72% of urothelial carcinoma patients [3].

RAD50 is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

RAD50 is altered in 2.62% of cervical carcinoma patients [3].

RAD50 is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

RAD50 is altered in 2.74% of colorectal carcinoma patients [3].

RAD50 is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

RAD50 is altered in 1.03% of pancreatic carcinoma patients [3].

RAD50 is an inclusion criterion in 3 clinical trials for pancreatic carcinoma, of which 3 are open and 0 are closed. Of the trials that contain RAD50 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

RAD50 is altered in 0.76% of soft tissue sarcoma patients [3].

RAD50 is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain RAD50 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.72% of esophageal carcinoma patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

RAD50 is altered in 1.74% of head and neck squamous cell carcinoma patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

RAD50 is altered in 0.99% of gastrointestinal stromal tumor patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.02% of squamous cell lung carcinoma patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].

RAD50 is altered in 1.17% of head and neck carcinoma patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for head and neck carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and head and neck carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.09% of high grade ovarian serous adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.28% of non-hodgkin lymphoma patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

RAD50 is altered in 0.43% of osteosarcoma patients [3].

RAD50 is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain RAD50 status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

RAD50 is altered in 3.09% of bladder urothelial carcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 3.09% of malignant small intestinal neoplasm patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 2.86% of anal carcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD50 is altered in 2.78% of colorectal adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 2.76% of malignant intestinal neoplasm patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.93% of esophageal adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.61% of gastric adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.67% of malignant esophagogastric neoplasm patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.59% of malignant gastric neoplasm patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.55% of clear cell renal cell carcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.78% of diffuse large B-cell lymphoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 1.79% of glioma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 1.57% of cancer patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.72% of malignant central nervous system neoplasm patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 1.25% of rhabdomyosarcoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 2.37% of mantle cell lymphoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 1.23% of biliary tract carcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.26% of malignant ovarian epithelial tumor patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.35% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 1.09% of bile duct adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 1.09% of cholangiocarcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 0.96% of invasive breast carcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 1.28% of B-cell non-hodgkin lymphoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 0.78% of medulloblastoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 0.73% of ampulla of vater carcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

RAD50 is altered in 0.66% of low grade ovarian serous adenocarcinoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 0.61% of neuroblastoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is altered in 1.69% of multiple myeloma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is altered in 0.9% of leiomyosarcoma patients [3].

RAD50 is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

RAD50 is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

RAD50 is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

RAD50 is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD50 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

RAD50 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RAD50 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].